Navigation Links
CNIO team presents a new strategy to personalise cancer therapies
Date:4/29/2014

Tumour cells can accumulate hundreds or even thousands of DNA mutations which induce the growth and spread of cancer. The number and pattern of mutations differs according to the type of tumour, even among those that are classified as part of the same type of tumours. This complexity, which researchers were not aware of just a few years ago, calls for new tools to filter relevant genetic information for the implementation and development of personalised therapies targeted at specific characteristics within each individual tumour.

Researchers led by Manuel Hidalgo, Vice-Director of Translational Research at CNIO, have developed a new strategy to personalised medicine in advanced cancer patients with a poor prognosis. The study has been published in the journal Clinical Cancer Research. Applying this new tool, the treatments induced clinical responses in up to 77% of patients, either through the stabilisation of their condition or through a partial clinical response.

During the first phase, the authors analysed the genetic signature of the tumours specifically, the hundreds of millions of letters that make up the exome; the part of the genome whose information produces proteins in 23 patients suffering from advanced cancers, such as pancreatic adenocarcinomas and colon cancer. By using whole exome sequencing and bioinformatics analyses, researchers picked out mutations that could play an important role in the growth and spread of tumours.

The second part of the study involved the use of Avatar mice to study potentially effective treatments according to the patient's genetic signature. As Elena Garralda, predoctoral researcher from Hidalgo's Group, points out, avatar mice are "one of the key aspects of our research."

AVATAR MICE: A TESTING GROUND FOR DRUGS

Avatar mice are used as a testing ground, with each patient having their own equivalent animal, in order to study the effectiveness of drugs under real
'/>"/>

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Report presents designs for study of cancer risks near US nuclear facilities
2. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
3. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
4. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
5. Crop Science Society of America presents 2012 class of fellows
6. IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management
7. Choline supplementation during pregnancy presents a new approach to schizophrenia prevention
8. July meeting presents animal and dairy science
9. Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting
10. Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients
11. Yin-yang effect of sodium and chloride presents salt conundrum
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CNIO team presents a new strategy to personalise cancer therapies
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/23/2015)... 23, 2015 Research and Markets ( ... "Global Outlook of the Biometrics Industry 2015 ... The global biometrics market is likely to ... applications owing to the uptake of multiple technologies ... that enhances the growth of biometrics in existing ...
(Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... an astonishing abundance, diversity and distribution of deep sea species ... a living in a frigid black world down to 5,000 ... via deep-towed cameras, sonar and other vanguard technologies, animals known ... a diverse collection of species ranging from crabs to shrimp ...
... 2009 Agios Pharmaceuticals today announced that its scientists ... IDH1 gene has a novel enzyme activity consistent with ... that the mutated form of IDH1 produces a metabolite, ... malignant progression of gliomas, the most common type of ...
... NJIT researchers are at work on many scientific and ... support that totals nearly $4.3 million for the diverse ... and Reinvestment Act of 2009. Four researchers ... Philip R. Goode, distinguished professor of physics, will enhance ...
Cached Biology News:Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 3Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 4Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 5Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 6Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 7Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 8Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 9Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2
(Date:8/5/2015)... , Aug. 5, 2015  MabVax Therapeutics Holdings, Inc. ... immuno-oncology drug development company, announces the posting of the ... Officer David Hansen to the Company,s website ... You have invested in MabVax Therapeutics because ... the treatment of difficult cancers.  You also share our ...
(Date:8/5/2015)... Switzerland (PRWEB) , ... August 05, 2015 , ... ... solutions for production, culture, and assessment of more organotypic 3D cell culture models, ... GravityTRAP™ Ultra-Low Attachment (ULA) Plates are now available for purchase exclusively ...
(Date:8/4/2015)... Aug. 4, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... financial results for the quarter ending June 30, 2015. Highlights ... in June 2015 , The final cost of ... or $4.0 million above the high end of the ... million +/- 10%) , The company announced commercial ...
(Date:8/4/2015)... ... August 04, 2015 , ... RPS Diagnostics (RPS®) ... today announced that Robert A. Gregg, PhD, has joined RPS as Senior Vice ... of relevant experience and remarkable achievements in the medical device and diagnostics industries. ...
Breaking Biology Technology:MabVax Therapeutics Issues Letter to Stockholders 2MabVax Therapeutics Issues Letter to Stockholders 3MabVax Therapeutics Issues Letter to Stockholders 4MabVax Therapeutics Issues Letter to Stockholders 5MabVax Therapeutics Issues Letter to Stockholders 6MabVax Therapeutics Issues Letter to Stockholders 7MabVax Therapeutics Issues Letter to Stockholders 8MabVax Therapeutics Issues Letter to Stockholders 9MabVax Therapeutics Issues Letter to Stockholders 10MabVax Therapeutics Issues Letter to Stockholders 11MabVax Therapeutics Issues Letter to Stockholders 12MabVax Therapeutics Issues Letter to Stockholders 13InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms 2InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms 3BioAmber Reports Second Quarter 2015 Financial Results 2BioAmber Reports Second Quarter 2015 Financial Results 3BioAmber Reports Second Quarter 2015 Financial Results 4BioAmber Reports Second Quarter 2015 Financial Results 5BioAmber Reports Second Quarter 2015 Financial Results 6BioAmber Reports Second Quarter 2015 Financial Results 7BioAmber Reports Second Quarter 2015 Financial Results 8BioAmber Reports Second Quarter 2015 Financial Results 9BioAmber Reports Second Quarter 2015 Financial Results 10BioAmber Reports Second Quarter 2015 Financial Results 11BioAmber Reports Second Quarter 2015 Financial Results 12RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3
... ... awarded a $2.18 million grant to Aciont Inc. to help fund its development of a ... ... The National Eye Institute (NEI), a division of the National Institutes of Health (NIH), awarded ...
... ... Brooks Instrument, a world-leading provider of advanced flow measurement, ... company as Global Level Product Manager effective November 30, 2009. He ... level measurement products around the world. He is joining Brooks Instrument ...
... , , SAN DIEGO, Dec. ... stabilization, today announces the release of SampleWare 3.1 software system ... latest release now includes an audit trail functionality that tracks ... of any stored sample. , The addition of the ...
Cached Biology Technology:NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3Biomatrica Launches SampleWare 3.1 2Biomatrica Launches SampleWare 3.1 3
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
... ( Abpromise for all tested ... Synthetic peptide derived from within residues ... MSY2/YBOX2. (Note: the amino acid ... (Peptide available as ab27460 .) ...
Biology Products: